The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting…
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…
CABP CE Eligible
Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity. Mechanistic insights into HSC biology could be leveraged to further improve the strategies available to maintain and expand functional HSCs in vitro. Overcoming these hurdles is critical to effectively use HSCs for off-the-shelf allogeneic HSC transplantation or gene-editing of autologous HSCs for treatments of hematological disease and malignancies. In this session, we will discuss the most recent applications of HSC expansion technology currently in clinical use. We will also explore the latest mechanistic breakthroughs towards producing abundant HSCs in vitro for use in transfusion applications.
Learning Objectives
Uncover latest mechanistic underpinnings of hematopoietic stem cell (HSC) cycling and maintenance of stem cell self-renewal in vitro.
Define the molecular mechanisms and that contribute to exhaustion of HSCs under tissue culture conditions.
Describe the latest advances in technologies and methods to expand functional HSCs and de novo generation of HSCs in vitro.
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
AM24-MN-34-O: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation (Enduring) Evaluation
Decentralized manufacturing has become a prominent focus in the Advanced Therapies space as the number of therapies in development increases and patient volumes surge with earlier line treatment objectives…
This informative session will give an overview of inspections conducted by FDA’s Office of Inspections and Investigations (OII), Office of Biologics Inspectorate (OBI), including OBI’s role in regulatory inspections and current regulatory oversight…
Despite the need for diverse donors of blood, stem cells, and organs/tissues, such donors remain dramatically underrepresented in donor pools, across donation products.. This session will begin with a brief didactic component, where expert presenters (Dr…
A presentation of how one facility tackled a massive inventory reduction project to discard cell therapy products that had been in LN2 storage for 10 to 25 years…